Compare CNXU & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNXU | IHD |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.7M | 133.2M |
| IPO Year | 2025 | N/A |
| Metric | CNXU | IHD |
|---|---|---|
| Price | $3.32 | $7.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 163.1K | 41.5K |
| Earning Date | 02-03-2027 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $5.93 |
| 52 Week High | $13.66 | $8.14 |
| Indicator | CNXU | IHD |
|---|---|---|
| Relative Strength Index (RSI) | 29.51 | 45.65 |
| Support Level | N/A | $7.44 |
| Resistance Level | $5.47 | $7.64 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 2.97 | 32.50 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.